keep away from direct sunlight,store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tranilast (SB 252218) 是一种抗过敏药物,可抑制炎症细胞释放脂质介质和细胞因子,抑制前列腺素 D2 (PGD2)产生,IC50为 0.1 mM。它拮抗血管紧张素 II 并抑制其在血管平滑肌细胞中的生物学作用,具有抗炎和免疫调节作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 197 | 现货 | ||
10 mg | ¥ 278 | 现货 | ||
25 mg | ¥ 428 | 现货 | ||
50 mg | ¥ 591 | 现货 | ||
100 mg | ¥ 747 | 现货 | ||
200 mg | ¥ 1,080 | 现货 | ||
500 mg | ¥ 1,850 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 213 | 现货 |
产品描述 | Tranilast (SB 252218), an antiallergic drug, suppresses lipid mediator and cytokine release from inflammatory cells, therefore utilized in the treatment of allergic disorders. |
靶点活性 | PGD2:0.1 mM (IC50) |
体外活性 | 在糖尿病大鼠的心脏中,Tranilast减少磷酸化Smad2, 能够降低心脏纤维化. |
体内活性 | 在瘢痕瘤和增生性瘢痕组织中, Tranilast(3-300 mM)通过抑制抑制转化生长因子(TGF)-β1,从而抑制成纤维细胞的胶原合成,但它不抑制正常的皮肤成纤维细胞。 |
激酶实验 | His-tagged human Mps1Cat encoding amino acids 510-857 is generated. For kinase assays, 500 ng is added to buffer (25 mM Tris-HCl, pH 7.4, 100 mM NaCl, 50 μg/mL BSA, 0.1 mM EGTA, 0.1% β-mercaptoethanol, 10 mM MgCl2, and 0.5 μg/mL myelin basic protein), AZ3146, and 100 μM γ-[32P]ATP (2 μCi/assay). Reactions are incubated at 30°C for 20 min, spotted onto P81 paper, washed in 0.5% phosphoric acid, and immersed in acetone. Phosphate incorporation is determined by scintillation counting. For immunoprecipitation kinase assays, HeLa cells are treated with nocodazole for 14 h, mitotic cells isolated, washed in PBS, and lysed for 30 min in 50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.5% NP-40, 5 mM EDTA, 5 mM EGTA, 40 mM β-glycerophosphate, 0.2 mM PMSF, 1 mM DTT, 1 mM sodium orthovanadate, 20 mM sodium fluoride, 1 μM okadaic acid, and complete EDTA-free protease inhibitor cocktail. Full-length Mps1 is immunoprecipitated. Purified complexes are washed with lysis buffer containing 100 mM NaCl and assayed as described for the recombinant protein. To quantify 32P incorporation, reactions are stopped with SDS sample buffer and separated by SDS-PAGE followed by phosphorimaging. The plate is analyzed using a phosphorimager using AIDA software. To assess the specificity of AZ3146, a single-point screen is carried using kinase profiling service. 50 kinases are selected and assayed with 1 μM AZ3146[1]. |
别名 | 曲尼司特, MK 341, SB 252218 |
分子量 | 327.33 |
分子式 | C18H17NO5 |
CAS No. | 53902-12-8 |
keep away from direct sunlight,store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 32.7 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.055 mL | 15.2751 mL | 30.5502 mL | 76.3755 mL |
5 mM | 0.611 mL | 3.055 mL | 6.11 mL | 15.2751 mL | |
10 mM | 0.3055 mL | 1.5275 mL | 3.055 mL | 7.6376 mL | |
20 mM | 0.1528 mL | 0.7638 mL | 1.5275 mL | 3.8188 mL | |
50 mM | 0.0611 mL | 0.3055 mL | 0.611 mL | 1.5275 mL | |
100 mM | 0.0306 mL | 0.1528 mL | 0.3055 mL | 0.7638 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Tranilast 53902-12-8 Endocrinology/Hormones GPCR/G Protein Immunology/Inflammation RAAS Prostaglandin Receptor Inhibitor endothelial chemotaxis tube MK341 anti-atopic prostaglandin SB252218 vascular Angiogenesis SB-252218 Angiotensin Receptor MK-341 proliferation inhibit microvascular 曲尼司特 MK 341 SB 252218 factor growth inhibitor